Compare MGM Resorts International (MGM) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MGM Resorts International vs 10X Genomics Inc — how do they compare? MGM Resorts International trades at $40.55 (market cap $10.25B), while 10X Genomics Inc trades at $67.8 (market cap $8.55B). The key difference: MGM Resorts International is the larger of the two by market cap, and MGM Resorts International pays a 0.03% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| MGM | TXG | |
|---|---|---|
Market Cap | $10.25B | $8.55B |
Sector | Consumer Cyclical | Health |
52-Week High | $50.69 | $67.29 |
52-Week Low | $30.72 | $11.34 |
Enterprise Value | $37.55B | $8.08B |
Dividend Yield | 0.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MGM Resorts International (MGM) trades at $40.74, down 1.16% on the day, with a bearish technical signal but bullish oscillators like RSI indicating potential oversold conditions. Revenue grew to $17.54B in 2025, though net income margin compressed to 2.4%. Recent news includes a $48.30 per share acquisition offer under investigation and BetMGM's football season enhancements, reflecting mixed operational and strategic developments.
The stock presents a valuation opportunity with a low P/S of 0.61 and strong analyst consensus price target of $51.61, but faces risks from declining profitability, high debt, and regulatory scrutiny. Upside hinges on execution in digital and international segments, while investor sentiment is cautious amid earnings volatility and acquisition uncertainty.
TXG trades at $65.60, up 4.71% today, with strong technical momentum showing bullish moving averages and key support at $63. Fundamentally, the company demonstrates improving trends with Q2 2026 earnings beating estimates and revenue growth guidance raised, though profitability remains negative with a -12.18% net margin. Recent patent victory against Parse Biosciences strengthens competitive positioning.
The outlook remains cautiously optimistic with analyst consensus at 45% buy ratings and $50.78 price target. Key opportunities include Atera platform adoption and consumables growth, while risks center on valuation premiums and ongoing profitability challenges. The stock trades near resistance at $67 with institutional interest showing mixed signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
